Grifols S.A. ADR Stock
Pros and Cons of Grifols S.A. ADR in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Grifols S.A. ADR vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Grifols S.A. ADR | 0.820% | 6.034% | -3.150% | -19.079% | -33.514% | -59.539% | -61.801% |
Beximco Pharmaceuticals Ltd. GDR | 7.140% | 7.143% | 7.143% | 7.143% | 2.273% | -52.381% | -21.053% |
Cellectar BioSciences Inc. | -4.670% | -10.063% | -12.270% | 120.000% | 25.439% | -73.519% | - |
Arca Biopharma | 3.140% | -0.613% | 11.724% | 67.876% | 108.360% | 21.805% | -94.286% |
Comments
Grifols, S.A. (NASDAQ: GRFS) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "sell" rating.
Show more
Ratings data for GRFS provided by MarketBeat